Leniolisib has a list price of £352,000 a year, but was approved as cost effective by the health regulator NICE after the NHS negotiated a substantial, confidential discount.
For reference: Daratumumab is a lot cheaper, and will probably become even cheaper when the patents runs out.
It is interesting to see how testing for APSD is quite strongly recommended, even before this treatment was available.
For Huntington’s disease (HD), which is inherited the same way, progressive, and eventually fatal, there is much more focus on everyone doing what’s right for them. I’m assuming the scales shift when you’ve got at least some treatment options like for APSD, and knowing if you’re positive might actually make a difference by getting access to treatments. The main concern for HD is if you want to test before you get children, and what a positive test might mean for children you’ve already got.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.